We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,050 | 22:29:19 |
By Stephen Nakrosis
Novartis AG (NVS) said Friday the U.S. Food and Drug Administration approved its drug Promacta for patients with a rare, life-threatening, acquired blood disorder and also gave it Breakthrough Therapy designation for low platelet counts in people exposed to radiation.
The FDA's approval of Promacta for first-line treatment of severe aplastic anemia, or SAA, was based on Novartis' analysis of research sponsored by the National Heart, Lung and Blood Institute Division of Intramural Research Program. Data showed a "compelling benefit established through complete response rates among SAA patients when Promacta is added to standard immunosuppressive therapy relative to historic information on that therapy alone," the company said.
Promacta is the first new treatment in decades for newly diagnosed SAA patients in the U.S., Novartis said, adding a decision by the European Medicines Agency is expected in 2019.
The FDA also granted Promacta Breakthrough Therapy designation as a counter measure for hematopoietic sub-syndrome of acute radiation syndrome, or H-ARS. Research and development of Promacta for H-ARS is being conducted under contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 16, 2018 17:22 ET (22:22 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions